1月12日 - ** 法国生物技术公司AbivaxABVX.PAABVX.O在美国上市的股票因新的收购传闻盘前上涨32%，达到151美元。
** 据法国媒体报导，美国制药巨头礼来LLY.N可能出价150亿欧元 (link) (175.2亿美元)收购Abivax，这几乎是其目前市值的两倍。
** Abivax和礼来公司没有立即回应路透的置评请求
** Abivax正在开发一种用于治疗溃疡性结肠炎的实验性药物奥贝昔莫德，其首席执行官曾表示，这种药物可能成为一种广泛应用的产品。
** 礼来公司与Abivax的首次收购传闻 (link) 于12月10日浮出水面。
** 2025年，ABVX飙升了1,749%。
(1美元=0.8560欧元)
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.